Exelon: Advanced Cognitive Support for Dementia Symptoms
| Product dosage: 3mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.16 (0%) | 🛒 Add to cart |
| 60 | $1.09 | $82.33 $65.26 (21%) | 🛒 Add to cart |
| 90 | $0.99 | $123.49 $89.36 (28%) | 🛒 Add to cart |
| 120 | $0.94 | $164.66 $112.45 (32%) | 🛒 Add to cart |
| 180 | $0.89 | $246.99 $159.64 (35%) | 🛒 Add to cart |
| 270 | $0.86 | $370.48 $230.92 (38%) | 🛒 Add to cart |
| 360 | $0.83
Best per pill | $493.98 $300.20 (39%) | 🛒 Add to cart |
| Product dosage: 6mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.57 | $47.19 (0%) | 🛒 Add to cart |
| 60 | $1.24 | $94.38 $74.30 (21%) | 🛒 Add to cart |
| 90 | $1.12 | $141.57 $100.40 (29%) | 🛒 Add to cart |
| 120 | $1.05 | $188.75 $126.51 (33%) | 🛒 Add to cart |
| 180 | $0.99 | $283.13 $178.71 (37%) | 🛒 Add to cart |
| 270 | $0.96
Best per pill | $424.70 $260.04 (39%) | 🛒 Add to cart |
Synonyms | |||
Exelon (rivastigmine) is a prescription medication specifically formulated for the treatment of mild to moderate dementia associated with Alzheimer’s disease and Parkinson’s disease. As a cholinesterase inhibitor, it works by increasing the levels of certain chemicals in the brain involved in memory, thinking, and reasoning. This medication is a cornerstone in the management of cognitive decline, helping to slow symptom progression and improve daily functioning in eligible patients. Clinical evidence supports its role in enhancing neurochemical communication, offering a targeted approach to symptom management under professional supervision.
Features
- Active ingredient: Rivastigmine
- Available formulations: Oral capsules, oral solution, and transdermal patches
- Standard capsule strengths: 1.5 mg, 3 mg, 4.5 mg, 6 mg
- Transdermal patch strengths: 4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hr
- Mechanism of action: Reversible cholinesterase inhibitor
- Half-life: Approximately 1.5 hours in plasma (with prolonged activity in CSF)
- Metabolism: Primarily via hepatic CYP enzymes
- Excretion: Renal elimination
Benefits
- Helps slow the progression of cognitive decline in Alzheimer’s and Parkinson’s disease dementia
- May improve memory, attention, and reasoning abilities
- Supports enhanced daily functioning and independence in patients
- Can contribute to stabilized behavioral symptoms
- Transdermal formulation offers alternative administration with potentially reduced gastrointestinal side effects
- Evidence-based therapeutic option with established clinical efficacy
Common use
Exelon is primarily indicated for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia associated with Parkinson’s disease. It is used to address core cognitive symptoms including memory impairment, disorientation, and difficulties with reasoning and judgment. The medication may also provide benefits in managing associated behavioral symptoms such as apathy, agitation, and mood disturbances. Treatment is typically initiated when symptoms begin to interfere with daily activities and social functioning, following comprehensive diagnostic evaluation by a qualified healthcare provider.
Dosage and direction
Initial dosing: Treatment should be initiated at 1.5 mg twice daily with food. After a minimum of two weeks, and if the initial dose is well tolerated, the dose may be increased to 3 mg twice daily. Subsequent increases to 4.5 mg and 6 mg twice daily should be based on tolerability, with minimum two-week intervals between dose escalations.
Maintenance dosing: The effective dosage range is 3-6 mg twice daily. Most patients derive maximum benefit at doses of 3-6 mg twice daily, though some may tolerate and benefit from higher doses.
Transdermal patch: Initial therapy begins with 4.6 mg/24 hr patch applied once daily. After a minimum of four weeks, if well tolerated, may increase to 9.5 mg/24 hr. The 13.3 mg/24 hr patch is reserved for patients with severe dementia who have been on 9.5 mg/24 hr for at least four weeks.
Administration guidelines: Capsules should be taken with food in the morning and evening. Transdermal patches should be applied to clean, dry, intact skin on the upper or lower back, upper arm, or chest, rotating application sites daily. Patches should be replaced every 24 hours.
Precautions
Patients should be closely monitored for gastrointestinal adverse effects, particularly during dose escalation. Weight should be monitored regularly due to potential for decreased appetite and weight loss. Use with caution in patients with history of ulcer disease or gastrointestinal bleeding. Pulmonary conditions such as asthma or COPD require careful monitoring due to potential increased bronchial secretions. Cardiac monitoring is advised in patients with cardiac conduction abnormalities or history of syncope. Patients should maintain adequate fluid intake to prevent dehydration. Transdermal patches may cause skin reactions; application site should be rotated daily.
Contraindications
Exelon is contraindicated in patients with known hypersensitivity to rivastigmine, other carbamate derivatives, or any components of the formulation. The medication is contraindicated in patients with severe liver impairment. Previous history of allergic contact dermatitis with rivastigmine patch use constitutes a contraindication for transdermal administration. Concurrent use with other cholinergic agents is generally contraindicated due to risk of excessive cholinergic stimulation.
Possible side effects
Very common (>10%): Nausea, vomiting, diarrhea, loss of appetite, weight loss, dizziness
Common (1-10%): Abdominal pain, dyspepsia, fatigue, weakness, tremor, sweating, insomnia, anxiety, agitation, depression, syncope, bradycardia
Uncommon (0.1-1%): Gastric and duodenal ulcers, gastrointestinal bleeding, dehydration, extrapyramidal symptoms, atrial fibrillation, AV block, hypertension, rash, pruritus
Rare (<0.1%): Pancreatitis, seizures, hepatitis, allergic reactions including anaphylaxis, neuroleptic malignant syndrome-like symptoms
Transdermal patch-specific: Application site reactions including erythema, pruritus, irritation, and vesiculation
Drug interaction
Anticholinergic agents: May decrease efficacy of Exelon Cholinergic agents: Increased risk of cholinergic toxicity Beta-blockers: Potential additive effect on bradycardia Neuromuscular blocking agents: May prolong neuromuscular blockade Nicotine: May increase rivastigmine clearance CYP3A4 inhibitors/inducers: Moderate effect on metabolism; monitor for efficacy changes Other centrally-acting drugs: Additive sedative or cognitive effects possible
Missed dose
If a dose is missed, it should be skipped and the next dose taken at the regularly scheduled time. Patients should not double the dose to make up for a missed dose. For transdermal patches, if a patch application is forgotten, a new patch should be applied as soon as remembered, then continue with regular daily changing schedule. Do not apply two patches simultaneously.
Overdose
Overdose may lead to severe nausea, vomiting, diarrhea, excessive salivation, sweating, bradycardia, hypotension, respiratory depression, syncope, and convulsions. Increasing muscle weakness may occur and can result in death if respiratory muscles are involved. Tertiary anticholinergics such as atropine may be used as an antidote. Initial recommended dose of atropine for adults is 0.03 mg/kg IV, with subsequent dosing based on clinical response. Supportive measures should include maintenance of vital functions, cardiac monitoring, and control of seizures if present.
Storage
Store at room temperature (15-30°C or 59-86°F). Keep capsules in their original container, tightly closed, and protect from moisture. Oral solution should be stored in refrigerator (2-8°C or 36-46°F); do not freeze. Transdermal patches should be kept in their sealed pouch until time of use. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Exelon is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual patient needs may vary, and treatment decisions should be made in consultation with a physician. The information provided here is not exhaustive; please refer to the full prescribing information for complete details. Never initiate, adjust, or discontinue medication without professional medical guidance.
Reviews
“Clinical trials demonstrate that Exelon provides statistically significant improvements in cognitive function and activities of daily living compared to placebo. In a 26-week study of patients with Alzheimer’s dementia, those treated with Exelon capsules showed significant improvement in ADAS-cog and CIBIC-plus scores. Transdermal formulation studies show improved tolerability profile while maintaining efficacy.”
“Long-term extension studies suggest sustained cognitive benefits over 52 weeks of treatment. Parkinson’s disease dementia trials showed significant improvements in attention, memory, and executive function. Real-world evidence supports the maintenance of treatment benefits in appropriate patient populations with acceptable safety profile when properly titrated.”